Key facts
- Praxis Precision Medicines announced Phase 2/3 POWER1 study findings.
- The study evaluated ulixacaltamide for paroxysmal kinesigenic dyskinesia.
- Results from the clinical trial are now available.
Praxis Precision Medicines has announced the findings from its Phase 2/3 POWER1 study. This clinical trial was designed to evaluate the efficacy of ulixacaltamide in patients diagnosed with paroxysmal kinesigenic dyskinesia. The study's results are now available.
